Reath hold were acquired and saved digitally. Strain analysis of LA

Reath hold were acquired and saved digitally. Strain analysis of LA and RA was performed offline with Siemens syngo US workplace (version 2, Siemens Medical Solutions USA). After manually defining the endocardial borderEchocardiographic FeaturesConventional transthoracic echocardiographic parameters of the study population are presented in Table 2. All the subjects had normal LV diastolic and DprE1-IN-2 web systolic dimensions. 2 patients with severe CAD were found with mild decreased LV systolic function (LVEF 45?0 ). However, there was no significant difference in LVEF or LVFS between 3 groups. The LA dimensions in control, mild CAD and severe CAD groups were 36.3664.07 mm,3PO chemical information atrial Deformation and Coronary Artery DiseaseFigure 1. Left atrial longitudinal strain/strain rate curves obtained from an apical four-chamber view. es: peak atrial longitudinal strain during ventricular systole, ea: atrial strain at the onset of P-wave on electrocardiography, SRs: peak left atrial strain during LV systole, SRe: peak left atrial strain during early LV diastole, SRa: peak left atrial strain during late LV diastole. doi:10.1371/journal.pone.0051204.gTable 1. Baseline clinical data.Variablecontrol group (n = 25)mild CAD group (n = 20) 67.6068.57 14 (70 ) 25.3964.96 72.25615.07 125.52617.62 73.66610.52 83.89615.08 4.9760.82 6.8362.96 5.4861.09 4.1461.1941 2.5161.52 2.4560.81 1.1760.36 97.23627.26 2.3663.23 5 (25 ) 3 (15 )severe CAD group (n = 40) 62.03612.39 25 (62.5 ) 23.2964.45 69.5669.89 133.37618.05 78.1369.24 77.03622.59 6.7262.45 7.7463.19 5.6561.89 5.0361.41 3.1762.22* 2.9061.34 0.9960.27 115.07636.34 2.3262.99 15 (37.5 ) 10 (22.2 )P ValueAge (y) Male gender BMI (kg/m2) Heart rate (min21) SBP (mmHg) DBP (mmHg) eGFR (ml/min/1.73 m2) FPG (mmol/L) 2-h oral glucose (mmol/L) HbA1c ( ) Cholesterol (mmol/L) Triglyceride (mmol/L) LDL-C (mmol/L) HDL-C (mmol/L) NT-proBNP (pg/ml) hs-CRP(mg/L) Current Smoking HT Medications ACEI and/or ARB Beta-blocker CCB60.5668.89 17 (68 ) 23.5467.05 73.4568.32 126.23614.2 77.44610.23 82.70616.67 5.7961.33 8.1063.17 6.3260.90 4.3160.94 2.0961.05 2.6260.91 1.0160.24 86.01623.21 2.1962.97 7 (28 ) 5 (20 )0.07 0.82 0.58 0.16 0.22 0.33 0.82 0.57 0.63 0.29 0.10 0.04 0.56 0.31 0.56 0.98 0.12 0.14 (56 ) 7 (28 ) 5 (20 )8 (40 ) 8 (40 ) 4 (20 )20 (50 ) 13 (32.5 ) 13 1676428 (32.5 )0.56 0.69 0.Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-CRP, high sensitivity C-reactive protein; HT, hypertension; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker. *p,0.05 versus control group. Abbreviated MDRD equation: estimated glomerular filtration rate (eGFR), in mL/min per 1.73 m2 = 186.36SCr (exp [21.154]) 6Age (exp[20.203]) 6(0.742 if female) 6 (1.21 if black). doi:10.1371/journal.pone.0051204.tAtrial Deformation and Coronary Artery DiseaseTable 2. Echocardiographic parameters in patients and controls.Variablescontrol group (n = 25)mild CAD group (n = 20) 32.5063.69 38.5064.15 49.0565.61 30.5564.92 10.0561.93 9.3061.26 90.46629.41 3.2461.10 37.8564.60 65.30611.16 69.00621.07 81.00618.73 213.72646.32 0.8860.31 8.2462.17 100.57635.severe CAD group (n 23115181 = 40) 31.9762.93 36.6864.74 47.1863.98 29.3363.12 10.0361.56 9.4061.53 79.88621.99 2.7460.90 37.8064.Reath hold were acquired and saved digitally. Strain analysis of LA and RA was performed offline with Siemens syngo US workplace (version 2, Siemens Medical Solutions USA). After manually defining the endocardial borderEchocardiographic FeaturesConventional transthoracic echocardiographic parameters of the study population are presented in Table 2. All the subjects had normal LV diastolic and systolic dimensions. 2 patients with severe CAD were found with mild decreased LV systolic function (LVEF 45?0 ). However, there was no significant difference in LVEF or LVFS between 3 groups. The LA dimensions in control, mild CAD and severe CAD groups were 36.3664.07 mm,Atrial Deformation and Coronary Artery DiseaseFigure 1. Left atrial longitudinal strain/strain rate curves obtained from an apical four-chamber view. es: peak atrial longitudinal strain during ventricular systole, ea: atrial strain at the onset of P-wave on electrocardiography, SRs: peak left atrial strain during LV systole, SRe: peak left atrial strain during early LV diastole, SRa: peak left atrial strain during late LV diastole. doi:10.1371/journal.pone.0051204.gTable 1. Baseline clinical data.Variablecontrol group (n = 25)mild CAD group (n = 20) 67.6068.57 14 (70 ) 25.3964.96 72.25615.07 125.52617.62 73.66610.52 83.89615.08 4.9760.82 6.8362.96 5.4861.09 4.1461.1941 2.5161.52 2.4560.81 1.1760.36 97.23627.26 2.3663.23 5 (25 ) 3 (15 )severe CAD group (n = 40) 62.03612.39 25 (62.5 ) 23.2964.45 69.5669.89 133.37618.05 78.1369.24 77.03622.59 6.7262.45 7.7463.19 5.6561.89 5.0361.41 3.1762.22* 2.9061.34 0.9960.27 115.07636.34 2.3262.99 15 (37.5 ) 10 (22.2 )P ValueAge (y) Male gender BMI (kg/m2) Heart rate (min21) SBP (mmHg) DBP (mmHg) eGFR (ml/min/1.73 m2) FPG (mmol/L) 2-h oral glucose (mmol/L) HbA1c ( ) Cholesterol (mmol/L) Triglyceride (mmol/L) LDL-C (mmol/L) HDL-C (mmol/L) NT-proBNP (pg/ml) hs-CRP(mg/L) Current Smoking HT Medications ACEI and/or ARB Beta-blocker CCB60.5668.89 17 (68 ) 23.5467.05 73.4568.32 126.23614.2 77.44610.23 82.70616.67 5.7961.33 8.1063.17 6.3260.90 4.3160.94 2.0961.05 2.6260.91 1.0160.24 86.01623.21 2.1962.97 7 (28 ) 5 (20 )0.07 0.82 0.58 0.16 0.22 0.33 0.82 0.57 0.63 0.29 0.10 0.04 0.56 0.31 0.56 0.98 0.12 0.14 (56 ) 7 (28 ) 5 (20 )8 (40 ) 8 (40 ) 4 (20 )20 (50 ) 13 (32.5 ) 13 1676428 (32.5 )0.56 0.69 0.Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-CRP, high sensitivity C-reactive protein; HT, hypertension; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker. *p,0.05 versus control group. Abbreviated MDRD equation: estimated glomerular filtration rate (eGFR), in mL/min per 1.73 m2 = 186.36SCr (exp [21.154]) 6Age (exp[20.203]) 6(0.742 if female) 6 (1.21 if black). doi:10.1371/journal.pone.0051204.tAtrial Deformation and Coronary Artery DiseaseTable 2. Echocardiographic parameters in patients and controls.Variablescontrol group (n = 25)mild CAD group (n = 20) 32.5063.69 38.5064.15 49.0565.61 30.5564.92 10.0561.93 9.3061.26 90.46629.41 3.2461.10 37.8564.60 65.30611.16 69.00621.07 81.00618.73 213.72646.32 0.8860.31 8.2462.17 100.57635.severe CAD group (n 23115181 = 40) 31.9762.93 36.6864.74 47.1863.98 29.3363.12 10.0361.56 9.4061.53 79.88621.99 2.7460.90 37.8064.